132910-79-3

Usage

Uses

Used in Pharmaceutical Research:
N-Boc-DL-Pipecolic acid methyl ester is used as a key intermediate in the synthesis of various drug candidates for [application reason]. Its unique structure and functional groups enable the development of novel therapeutic agents with improved pharmacological properties and therapeutic potential.
Used in Organic Synthesis:
In the field of organic synthesis, N-Boc-DL-Pipecolic acid methyl ester is employed as a versatile building block for [application reason]. The Boc protecting group allows for selective reactions to occur at other sites on the molecule, while the methyl ester group can be readily converted into other functional groups, facilitating the synthesis of complex organic compounds.
Used in Chemical Industry:
N-Boc-DL-Pipecolic acid methyl ester is utilized as a valuable intermediate in the chemical industry for [application reason]. Its ability to undergo various chemical transformations makes it an essential component in the production of a wide range of chemical products, including specialty chemicals, agrochemicals, and materials.

Upstream product

• 32559-18-5 methyl piperidine-2-carboxylate hydrochloride 
• 24608-52-4 tert-butyl chloroformate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 35677-83-9 methyl pipecolinate 
• 98303-20-9 1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid 
• 74-88-4 methyl iodide 
• 4043-87-2 pipecolic Acid 
• 77-78-1 dimethyl sulfate 
• 79-22-1 methyl chloroformate 
• 123387-55-3 1-t-butoxycarbonyl-2-tributylstannylpiperidine 
• 130622-09-2 (+/-) methyl N-tert-butyloxycarbonyl 6-oxo-2-piperidinecarboxylate 
• 1025782-34-6 6-hydroxypiperidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 

Downstream Products

• 157634-02-1 tert-butyl 2-formylpiperidine-1-carboxylate 
• 157634-00-9 tert-butyl 2-(hydroxymethyl)piperidine-1-carboxylate 
• 183859-36-1 methyl (+/-)-N-(tert-butyloxycarbonyl)piperidin-2-ylacetate 
• 1217-18-1 9-benzoyl-9-azabicyclo[3.3.1]nonan-2-one 
• 470669-09-1 9-benzoyl-1-methyl-9-azabicyclo[3.3.1]non-3-ene 
• 470669-28-4 9-benzoyl-2-methylene-9-azabicyclo[3.3.1]nonane 
• 470669-30-8 9-benzoyl-1-methyl-9-azabicyclo[3.3.1]nonan-4-one 
• 470669-29-5 9-benzoyl-1-methyl-4-methylene-9-azabicyclo[3.3.1]nonane 
• 470669-26-2 9-benzoyl-4-(trimethylsilylmethylene)-9-azabicyclo[3.3.1]nonane 
• 470669-27-3 9-benzoyl-1-methyl-4-(trimethylsilylmethylene)-9-azabicyclo[3.3.1]nonane 

Relevant academic research and scientific papers

Synthesis of 5-substituted pipecolic acid derivatives as new conformationally constrained ornithine and arginine analogues

Two, orthogonally protected, constrained analogues of arginine have been synthesised in a diastereodivergent manner. The key step involved an electrophilic or radical functionalisation of methyl N-Boc-5,6- dehydropipecolate.

Design and Synthesis of 56 Shape-Diverse 3D Fragments

Fragment-based drug discovery is now widely adopted for lead generation in the pharmaceutical industry. However, fragment screening collections are often predominantly populated with flat, 2D molecules. Herein, we describe a workflow for the design and synthesis of 56 3D disubstituted pyrrolidine and piperidine fragments that occupy under-represented areas of fragment space (as demonstrated by a principal moments of inertia (PMI) analysis). A key, and unique, underpinning design feature of this fragment collection is that assessment of fragment shape and conformational diversity (by considering conformations up to 1.5 kcal mol?1 above the energy of the global minimum energy conformer) is carried out prior to synthesis and is also used to select targets for synthesis. The 3D fragments were designed to contain suitable synthetic handles for future fragment elaboration. Finally, by comparing our 3D fragments with six commercial libraries, it is clear that our collection has high three-dimensionality and shape diversity.

AROMATIC ACETYLENE OR AROMATIC ETHYLENE COMPOUND, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Disclosed are an aromatic acetylene or aromatic ethylene compound, an intermediate, a preparation method, a pharmaceutical composition and a use thereof. The aromatic acetylene or aromatic ethylene compound has a significant inhibitory effect on PD-1 and PD-L1, and can effectively relieve or treat cancers and other related diseases.

Selective conversion of primary amides to esters promoted by KHSO4

Primary amides, either aliphatic or aromatic, are easily converted to the corresponding esters via reflux in lower primary alcohols in the presence of KHSO4. Secondary amides lead to complicated mixtures under analogous conditions, whereastertiary amides were inert. Use of isopropyl alcohol resulted inthe formation of product atslower rate and lower yieldalong withside products, whereas, use of tertiary alcoholsdid not give successful conversion andallyl and benzyl alcohol provided complex mixtures.

Stereoselective Synthesis of Tricyclic Diproline Analogues that Mimic a PPII Helix: Structural Consequences of Ring-Size Variation

Polycyclic proline-derived scaffolds (ProMs) have recently demonstrated their value as conformationally defined dipeptide analogs for the modular construction of secondary structure mimetics, specifically interfering with PPII helix-mediated protein-protein interactions. We disclose the stereoselective synthesis of two new tricyclic amino acid scaffolds (ProM-4 and ProM-8) that differ from the first generation scaffold ProM-1 by the size of ring A. Conformational preferences and subtle structural differences of the three homologous scaffolds were analyzed by X-ray crystallography, computational calculations, and NMR spectroscopy. N-tert-butoxycarbonyl(Boc)-3-(1-propenyl)azetidine-2-carboxylic acid was prepared from L-aspartic acid through β-lactam intermediates. The corresponding piperidine-based building block rac-N-Boc-3-vinylpipecolic acid was synthesized by Cu-catalyzed 1,4-addition of vinyl-MgBr to methyl N-Boc-2,3-dehydropipecolate. Target molecules were prepared through peptide coupling of the respective ring A building blocks with cis-5-vinylproline tert-butyl ester and subsequent ring-closing metathesis. Selective deprotection of a tert-butyl carbamate (N-Boc protecting group) in the presence of a tert-butyl ester was achieved with trifluoroacetic acid at 0 C. Two new tricyclic amino acid scaffolds, which differ from the first generation scaffold by the size of ring A, were stereoselectively synthesized. The conformational analysis of the three homologous scaffolds was revealed by NMR spectroscopy.

Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce α-synuclein phosphorylation in rat brain

Polo-like kinase-2 (Plk-2) has been implicated as the dominant kinase involved in the phosphorylation of α-synuclein in Lewy bodies, which are one of the hallmarks of Parkinson's disease neuropathology. Potent, selective, brain-penetrant inhibitors of Plk

PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE

The present invention provides compounds having a structure according to Formula (I) or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.

Asymmetric deprotonation of N -boc piperidine: React IR monitoring and mechanistic aspects

The high yielding asymmetric deprotonation trapping of N-Boc piperidine is successfully realized using s-BuLi and a (+)-sparteine surrogate. Monitoring of the lithiation by in situ React IR allowed the direct observation of a prelithiation complex.

MGLUR5 MODULATORS II

The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

MGluR5 modulators I

The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.